Publication
Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial.
Shuiqing He, Wei-Xin Bei, Nian Lu, Ze-Yu Zhao, Yanfang Ye, Chunyan Chen, Linquan Tang, Liting Liu, Shuhui Lv, Yan-Qun Xiang, Lin Wang
- Source
- PubMed
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260918-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) who progress after immune checkpoint inhibitor (ICI) therapy have limited treatment options and poor outcomes. We evaluated the efficacy and safety of liposomal irinotecan plus nimotuzumab in patients with…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT06414577registry_reference1.00
Registered trialsNCT06414577
Curated evidence
Evidence citing this paper (0)
Data not yet available